{
    "nctId": "NCT05030038",
    "briefTitle": "Oral Aromatase Inhibitors Modify the Gut Microbiome",
    "officialTitle": "Oral Aromatase Inhibitors Modify the Gut Microbiome Effecting Estrogen Bioavailability",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 25,
    "primaryOutcomeMeasure": "Change in Gut Microbial Levels - Fecal Swab",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Pathologic diagnosis in situ or invasive breast cancer for which initiating aromatase inhibitors therapy is recommended or initiating aromatase inhibitors for risk reduction.\n* ECOG performance status 0,1, 2, 3.\n* Age \u2265 18 years\n* HER2+ breast cancer is allowed if patients are on a monoclonal antibody therapy for which a change is not anticipated while on study (12 weeks) and they have been on the monoclonal antibody therapy for at least 4 weeks.\n* Ability to read, understand and evaluate study materials and willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Have been on antibiotics within 4 weeks of enrollment.\n* Administered chemotherapy less than 4 weeks prior to enrollment.\n* Hormone replacement (defined as only estrogen and/or progesterone replacement) or anti-estrogen therapy within 4 weeks of starting aromatase inhibitors\n* Use of antibody drug conjugate (HER2+ breast cancer)\n* Male breast cancer\n* Any serious and/or unstable pre-existing medical, psychiatric, or other existing condition that would prevent compliance with the trial or consent process",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}